Co-led the new investment in Rectify Pharmaceuticals, which launched with a $100M Series A.
Rectify Pharma develops Positive Functional Modulators (PFMs), a novel class of disease-modifying oral, small molecules designed to rectify membrane protein dysfunction linked to serious diseases
Rectify Pharma develops Positive Functional Modulators (PFMs), a novel class of disease-modifying oral, small molecules designed to rectify membrane protein dysfunction linked to serious diseases.